The Pharma Data

DECEMBER 23, 2020

Joseph Kim , President and CEO of INOVIO, said, “We are very pleased to share peer-reviewed Phase 1 clinical data for INO-4800 published in The Lancet’s EClinicalMedicine , and are grateful for the support of all participants and investigator staff involved in the clinical trial.” . PLYMOUTH MEETING, Pa. ,

DNA 40

DNA Vaccination Vaccine Immune Response 40

The Pharma Data

MARCH 25, 2022

People not adequately protected by a COVID-19 vaccine may particularly benefit from pre-exposure prophylaxis with Evusheld. 2-4 Evusheld was generally well-tolerated in the trial.(2-4). This includes about three million people in the EU who are immunocompromised or being treated with immunosuppressive medicines.(1).

Antibody 52

Antibody In-Vivo Medicine Vaccination 52

The Pharma Data

MARCH 29, 2022

Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months Evusheld retains neutralising activity against the Omicron BA.2 1-3 Evusheld was generally well-tolerated in the trial. 2 subvariant, now the dominant strain in Europe. Christoph D.

Antibody 52

Antibody In-Vivo Vaccination Vaccine 52

The Pharma Data

MAY 16, 2021

Adjuvanted recombinant COVID-19 vaccine candidate triggered strong neutralizing antibody responses in all adult age groups. High immune response after a single dose in patients with prior infection shows strong booster potential. Global Phase 3 study expected to start in the coming weeks. 1.351 (South African) variants.

Immune Response 52

Immune Response Vaccination Vaccine Trials 52

Bioengineer

JULY 15, 2021

. “We’re excited–with such low doses of radiation, we didn’t expect the response to be so positive,” said lead author Ravi Patel, M.D., “In clinical trials, we tend to go with the maximum tolerable dose, the idea being that radiation kills the cancer and the more we give, the better. ” ###.

Medicine 52

Medicine Clinical Trials Clinical Trials Scientist 52

The Pharma Data

AUGUST 22, 2021

The trial accrued 25 cases of symptomatic COVID-19 at the primary analysis.There were no cases of severe COVID-19 or COVID-19-related deaths in those treated with AZD7442. The trial included 5,197 participants in a 2:1 randomisation AZD7442 to placebo. The trial was conducted in 87 sites in the US, UK, Spain, France and Belgium.

Trials 52

Trials Antibody Vaccination Vaccine 52

XTalks

SEPTEMBER 14, 2020

“Vaccine Nationalism” Could Prove the Undoing of COVID-19 Containment. Tension is mounting as nations big and small jockey around industry to ensure they are first in line to access a vaccine, should one prove to be successful against COVID-19. Moderna’s COVID-19 Vaccine. The price of that prize is incalculable.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92